Stiripentol is an anticonvulsant medication primarily utilized as an adjunctive therapy in the treatment of Dravet syndrome and other forms of refractory epilepsy, often administered in combination with… Read more
![Chemical structure of (E)-1-(benzo[d][1,3]dioxol-4-yl)-4,4-dimethylpent-1-en-3-ol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FE-1-benzod13dioxol-4-yl-44-dimethylpent-1-en-3-ol.png&w=3840&q=75)
![Chemical structure of (E)-1-(Benzo[d][1,3]dioxol-5-yl)-4,4-dimethylpent-1-en-3-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F144850-45-3-E-1-Benzod13dioxol-5-yl-44-dimethylpent-1-en-3-one.png&w=3840&q=75)


![Chemical structure of 1-(Benzo[d][1,3]dioxol-5-yl)-4,4-dimethylpentan-3-ol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F106175-03-5-1-Benzod13dioxol-5-yl-44-dimethylpentan-3-ol.png&w=3840&q=75)








Stiripentol is an anticonvulsant medication primarily utilized as an adjunctive therapy in the treatment of Dravet syndrome and other forms of refractory epilepsy, often administered in combination with clobazam and valproic acid. For pharmaceutical laboratories, accurate analytical testing and quality control require specialized reference standards to ensure the safety and efficacy of the drug product. This category includes Stiripentol in its active pharmaceutical ingredient (API) form, alongside a comprehensive range of related synthetic impurities, metabolic derivatives such as glucuronides, and stable isotope labelled compounds. These materials are essential for conducting rigorous impurity profiling, establishing validated analytical methods, and performing reliable quantitative analysis using mass spectrometry. By serving as critical controls in bioanalytical studies and stability testing, these compounds allow for the precise monitoring of drug metabolism and the identification of potential degradation products during pharmaceutical development.